Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target

References

• Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803–820. PubMed PMID: 27157931.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20(suppl_4):iv1–iv86.
   PubMed Web of Science ®Google Scholar
• Castellano A, Cirillo S, Bello L, et al. Functional MRI for Surgery of Gliomas. Current treatment options in neurology. J Clin Oncol. 2017 Aug 23;19(10):34. PubMed PMID: 28831723; eng.
   Google Scholar
• Abhinav K, Yeh FC, Mansouri A, et al. High-definition fiber tractography for the evaluation of perilesional white matter tracts in high-grade glioma surgery. Neuro Oncol. 2015 Sep;17(9):1199–1209. PubMed PMID: 26117712; PubMed Central PMCID: PMCPMC4588761. eng.
   PubMed Web of Science ®Google Scholar
• Brown TJ, Brennan MC, Li M, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and Meta-analysis. JAMA Oncol. 2016 Nov 1;2(11):1460–1469. PubMed PMID: 27310651; eng.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009 Jan;110(1):156–162. PubMed PMID: 18847342.
   PubMed Web of Science ®Google Scholar
• Duffau H. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien). 2016 Jan;158(1):51–58. PubMed PMID: 26530708; eng.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765–773. PubMed PMID: 19228619; PubMed Central PMCID: PMCPMC2820383. eng.
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009 Oct 1;15(19):6002–6007. PubMed PMID: 19755387; eng.
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009 Oct;118(4):469–474. PubMed PMID: 19554337.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997–1003. PubMed PMID: 15758010; eng.
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000 Nov 9;343(19):1350–1354. PubMed PMID: 11070098.
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Young DF. Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol. 1976 Jul;33(7):494–500. PubMed PMID: 180938; eng.
   PubMedGoogle Scholar
• Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980 Dec 4;303(23):1323–1329. PubMed PMID: 7001230; eng.
   PubMed Web of Science ®Google Scholar
• Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983 Sep 15;52(6):997–1007. PubMed PMID: 6349785; eng.
   PubMed Web of Science ®Google Scholar
• Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas–re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 1988;(6):279–284. PubMed PMID: 3281031; eng.
   PubMedGoogle Scholar
• Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405–1409. PubMed PMID: 2542195; eng.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996. PubMed PMID: 15758009; eng.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. Jama. 2015 Dec 15;314(23):2535–2543. PubMed PMID: 26670971.
   PubMed Web of Science ®Google Scholar
• Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003 Dec;30(6 Suppl 19):10–14. PubMed PMID: 14765378; eng.
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012 Jul;13(7):707–715. PubMed PMID: 22578793; eng.
   PubMed Web of Science ®Google Scholar
• Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916–926. PubMed PMID: 22877848; eng.
   PubMed Web of Science ®Google Scholar
• Gallego Perez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011 Aug 1;29(22):3050–3055. PubMed PMID: 21709196; eng.
   PubMed Web of Science ®Google Scholar
• Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027–1037. PubMed PMID: 28296618; eng.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013 Jan 20;31(3):337–343. PubMed PMID: 23071247; PubMed Central PMCID: PMCPMC3732012. eng.
   PubMed Web of Science ®Google Scholar
• van Den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013 Jan 20;31(3):344–350. PubMed PMID: 23071237; eng.
   PubMed Web of Science ®Google Scholar
• Jaeckle K, Vogelbaum M, Ballman K, et al. CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic oligodendroglial tumors. analysis of patients treated on the original protocol design (PL02.005). Neurology. 2016;86(16Supplement):PL02.005.
   Google Scholar
• van Den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017 Oct 7;390(10103):1645–1653. PubMed PMID: 28801186; PubMed Central PMCID: PMCPMC5806535. eng.
   PubMed Web of Science ®Google Scholar
• Aghi MK, Nahed BV, Sloan AE, et al. The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015 Dec;125(3):503–530. PubMed PMID: 26530265; eng.
   PubMed Web of Science ®Google Scholar
• van Den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005 Sep 17- 23;366(9490):985–990. PubMed PMID: 16168780; eng.
   PubMed Web of Science ®Google Scholar
• Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016 Apr 7;374(14):1344–1355. PubMed PMID: 27050206; PubMed Central PMCID: PMCPMC5170873. eng.
   PubMed Web of Science ®Google Scholar
• Jiang T, Mao Y, Ma W, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2016 Jun 1;375(2):263–273. PubMed PMID: 26966000; eng.
   PubMed Web of Science ®Google Scholar
• Weller M, van Den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014 Aug;15(9):e395–403. PubMed PMID: 25079102; eng.
   PubMed Web of Science ®Google Scholar
• Santosh V, Sravya P, Gupta T, et al. ISNO consensus guidelines for practical adaptation of the WHO 2016 classification of adult diffuse gliomas. Neurol India. 2019 Jan–Feb;67(1):173–182. PubMed PMID: 30860119; eng.
   PubMed Web of Science ®Google Scholar
• Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011 Mar;121(3):397–405. PubMed PMID: 21274720; eng.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Preusser M. BRAF alterations in brain tumours: molecular pathology and therapeutic opportunities. Curr Opin Neurol. 2014 Dec;27(6):689–696. PubMed PMID: 25268071; eng.
   PubMed Web of Science ®Google Scholar
• Schiffman JD, Hodgson JG, VandenBerg SR, et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010 Jan 15;70(2):512–519. PubMed PMID: 20068183; PubMed Central PMCID: PMCPMC2851233. eng.
   PubMed Web of Science ®Google Scholar
• Kaley T, Touat M, Subbiah V, et al. BRAF inhibition in BRAF(V600)-Mutant gliomas: results from the VE-BASKET study. J Clin Oncol. 2018 Oct 23:Jco2018789990. PubMed PMID: 30351999; eng. DOI:10.1200/jco.2018.78.9990
   PubMed Web of Science ®Google Scholar
• Preusser M, Bienkowski M, Birner P. BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors. Expert Opin Investig Drugs. 2016;25(1):7–14. PubMed PMID: 26536389; eng.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Chmielecki J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016 Feb 15;138(4):881–890. PubMed PMID: 26314551; PubMed Central PMCID: PMCPMC5049644. eng.
   PubMed Web of Science ®Google Scholar
• Venneti S, Huse JT. The evolving molecular genetics of low-grade glioma. Adv Anat Pathol. 2015 Mar;22(2):94–101. PubMed PMID: 25664944; PubMed Central PMCID: PMCPMC4667550.
   PubMed Web of Science ®Google Scholar
• Maraka S, Janku F. BRAF alterations in primary brain tumors. Discov Med. 2018 Aug;26(141):51–60. PubMed PMID: 30265855; eng.
   PubMed Web of Science ®Google Scholar
• Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell. 2018 Aug 13;34(2):186–195. PubMed PMID: 29805076; PubMed Central PMCID: PMCPMC6092238. eng.
   PubMed Web of Science ®Google Scholar
• Turcan S, Makarov V, Taranda J, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet. 2018 Jan;50(1):62–72. PubMed PMID: 29180699; PubMed Central PMCID: PMCPMC5769471. eng.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 Oct;12(10):2013–2021. PubMed PMID: 7931469; eng.
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998 Oct 7;90(19):1473–1479. PubMed PMID: 9776413; eng.
   PubMed Web of Science ®Google Scholar
• Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006 Oct 15;66(20):9852–9861. PubMed PMID: 17047046; eng.
   PubMed Web of Science ®Google Scholar
• van Den Bent MJ, Smits M, Kros JM, et al. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol. 2017 Jul 20;35(21):2394–2401. PubMed PMID: 28640702; eng.
   PubMed Web of Science ®Google Scholar
• Cahill DP, Louis DN, Cairncross JG. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncol. 2015;4(5):287–294. PubMed PMID: 26545048; PubMed Central PMCID: PMCPMC6082339. eng.
   PubMedGoogle Scholar
• Lewis PW, Elsaesser SJ, Noh KM, et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14075–14080. PubMed PMID: 20651253; PubMed Central PMCID: PMCPMC2922592. eng.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber J, Korshunov A, Liu X-Y, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 Jan 29;482(7384):226–231. PubMed PMID: 22286061; eng.
   PubMed Web of Science ®Google Scholar
• Liu X-Y, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 2012 Nov;124(5):615–625. PubMed PMID: 22886134; eng.
   PubMed Web of Science ®Google Scholar
• Heidenreich B, Kumar R. TERT promoter mutations in telomere biology. Mutat Res. 2017 Jan - Mar;771:15–31. PubMed PMID: 28342451; eng.
   PubMed Web of Science ®Google Scholar
• Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021–6026. PubMed PMID: 23530248; PubMed Central PMCID: PMCPMC3625331. eng.
   PubMed Web of Science ®Google Scholar
• Vuong HG, Altibi AMA, Duong UNP, et al. TERT promoter mutation and its interaction with IDH mutations in glioma: combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. Crit Rev Oncol Hematol. 2017 Dec;120:1–9. PubMed PMID: 29198322; eng.
   PubMed Web of Science ®Google Scholar
• Chan AK-Y, Yao Y, Zhang Z, et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol. 2015 Feb;28(2):177–186. PubMed PMID: 25081751; eng.
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462–477. PubMed PMID: 24120142; PubMed Central PMCID: PMCPMC3910500.
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016 Jan 28;164(3):550–563. PubMed PMID: 26824661; PubMed Central PMCID: PMCPMC4754110. eng.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1):98–110. PubMed PMID: 20129251; PubMed Central PMCID: PMCPMC2818769. eng.
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006 Mar;9(3):157–173. PubMed PMID: 16530701; eng.
   PubMed Web of Science ®Google Scholar
• Everhard S, Tost J, El Abdalaoui H, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 2009 Aug;11(4):348–356. PubMed PMID: 19224763; PubMed Central PMCID: PMCPMC2743215. eng.
   PubMed Web of Science ®Google Scholar
• Bell EH, Pugh SL, McElroy JP, et al. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG oncology RTOG 0525. JAMA Oncol. 2017 Jun 1;3(6):784–792. PubMed PMID: 28097324; PubMed Central PMCID: PMCPMC5464982. eng.
   PubMed Web of Science ®Google Scholar
• Thon N, Thorsteinsdottir J, Eigenbrod S, et al. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. J Neurol. 2017 Feb;264(2):350–358. PubMed PMID: 27921166; eng.
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510–522. PubMed PMID: 20399149; PubMed Central PMCID: PMCPMC2872684. eng.
   PubMed Web of Science ®Google Scholar
• Wu F, Chai RC, Wang Z, et al. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles. Carcinogenesis. 2019 Feb 13. PubMed PMID: 30877769; eng. DOI:10.1093/carcin/bgz032
   Web of Science ®Google Scholar
• Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005 Feb 15;11(4):1462–1466. PubMed PMID: 15746047.
   PubMed Web of Science ®Google Scholar
• Felsberg J, Hentschel B, Kaulich K, et al. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res. 2017 Nov 15;23(22):6846–6855. PubMed PMID: 28855349; eng.
   PubMed Web of Science ®Google Scholar
• Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun;17(6):854–861. PubMed PMID: 25586468; PubMed Central PMCID: PMCPMC4483122.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.
   PubMed Web of Science ®Google Scholar
• van Den Bent MJ, Gao Y, Kerkhof M, et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol. 2015 Jul;17(7):935–941. PubMed PMID: 25691693; PubMed Central PMCID: PMCPMC5762005. eng.
   PubMed Web of Science ®Google Scholar
• Hundsberger T, Reardon DA, Wen PY. Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther. 2017 Jun;17(6):507–515. PubMed PMID: 28438066.
   PubMed Web of Science ®Google Scholar
• Lu-Emerson C, Duda DG, Emblem KE, et al. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 1;33(10):1197–1213. PubMed PMID: 25713439; PubMed Central PMCID: PMCPMC4517055.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669–676. PubMed PMID: 12778165.
   PubMed Web of Science ®Google Scholar
• Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol. 2012 Dec;124(6):763–775. PubMed PMID: 23143192; PubMed Central PMCID: PMCPMC3508273.
   PubMed Web of Science ®Google Scholar
• Zhou Y-H, Tan F, Hess KR, et al. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res. 2003 Aug 15;9(9):3369–3375. PubMed PMID: 12960124.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733–4740. PubMed PMID: 19720927.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb 10;27(5):740–745. PubMed PMID: 19114704; PubMed Central PMCID: PMCPMC2645088.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709–722. PubMed PMID: 24552318.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699–708. PubMed PMID: 24552317; PubMed Central PMCID: PMCPMC4201043.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10;28(11):1963–1972. PubMed PMID: 20231676; eng.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, Di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10;28(17):2817–2823. PubMed PMID: 20458050; PubMed Central PMCID: PMCPMC2903316.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10;31(26):3212–3218. PubMed PMID: 23940216; PubMed Central PMCID: PMCPMC4021043.
   PubMed Web of Science ®Google Scholar
• Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999 Sep 20;18(38):5356–5362. PubMed PMID: 10498889.
   PubMed Web of Science ®Google Scholar
• Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998 Nov;153(5):1459–1466. PubMed PMID: 9811337; PubMed Central PMCID: PMCPMC1853417.
   PubMed Web of Science ®Google Scholar
• Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol. 1999 Oct;159(2):391–400. PubMed PMID: 10506510.
   PubMed Web of Science ®Google Scholar
• Peterson TE, Kirkpatrick ND, Huang Y, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4470–4475. PubMed PMID: 27044097; PubMed Central PMCID: PMCPMC4843449.
   PubMed Web of Science ®Google Scholar
• Chae SS, Kamoun WS, Farrar CT, et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res. 2010 Jul 15;16(14):3618–3627. PubMed PMID: 20501615; PubMed Central PMCID: PMCPMC2905497.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013 Jun 10;31(17):2205–2218. PubMed PMID: 23669226; PubMed Central PMCID: PMCPMC3731977.
   PubMed Web of Science ®Google Scholar
• Piao Y, Liang J, Holmes L, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 2012 Nov;14(11):1379–1392. PubMed PMID: 22965162; PubMed Central PMCID: PMCPMC3480262.
   PubMed Web of Science ®Google Scholar
• Kuang R, Jahangiri A, Mascharak S, et al. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight. 2017 Jan 26;2(2):e88815. PubMed PMID: 28138554; PubMed Central PMCID: PMCPMC5256137.
   PubMed Web of Science ®Google Scholar
• Hamza MA, Gilbert M. Targeted therapy in gliomas. Curr Oncol Rep. 2014 Apr;16(4):379. PubMed PMID: 24510741.
   PubMed Web of Science ®Google Scholar
• Furnari FB, Cloughesy TF, Cavenee WK, et al. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015 May;15(5):302–310. PubMed PMID: 25855404; PubMed Central PMCID: PMCPMC4875778.
   PubMed Web of Science ®Google Scholar
• Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol. 2004 Jul;63(7):700–707. PubMed PMID: 15290895.
   PubMed Web of Science ®Google Scholar
• Montano N, Cenci T, Martini M, et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia. 2011 Dec;13(12):1113–1121. PubMed PMID: 22241957; PubMed Central PMCID: PMCPMC3257186.
   PubMed Web of Science ®Google Scholar
• Padfield E, Ellis Hp, Kurian Km. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol. 2015;5:5. pubmed pmid: 25688333; pubmed central pmcid: pmcpmc4310282. DOI:10.3389/fonc.2015.00005
   PubMed Web of Science ®Google Scholar
• Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009 Sep;20(9):1596–1603. PubMed PMID: 19491283.
   PubMed Web of Science ®Google Scholar
• Westphal M, Heese O, Steinbach JP, et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015 Mar;51(4):522–532. PubMed PMID: 25616647.
   PubMed Web of Science ®Google Scholar
• Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: mayo/North Central cancer treatment group study N0074. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):347–353. PubMed PMID: 20510539; PubMed Central PMCID: PMCPMC5753591.
   PubMed Web of Science ®Google Scholar
• Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer. 2007 Apr 10;96(7):1047–1051. PubMed PMID: 17353924; PubMed Central PMCID: PMCPMC2360116.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Abrey LE, Lassman AB, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010 Jan;12(1):95–103. PubMed PMID: 20150372; PubMed Central PMCID: PMCPMC2940554.
   PubMed Web of Science ®Google Scholar
• Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010 Jan;65(2):353–361. PubMed PMID: 19499221.
   PubMed Web of Science ®Google Scholar
• Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May;2(5):458–471. PubMed PMID: 22588883; PubMed Central PMCID: PMCPMC3354723.
   PubMed Web of Science ®Google Scholar
• Fenton TR, Nathanson D, Ponte de Albuquerque C, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164–14169. PubMed PMID: 22891331; PubMed Central PMCID: PMCPMC3435194.
   PubMed Web of Science ®Google Scholar
• Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010 Apr;223(1):14–26. PubMed PMID: 20049846.
   PubMed Web of Science ®Google Scholar
• Franceschi E, Stupp R, van Den Bent MJ, et al. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro Oncol. 2012 Dec;14(12):1503–1510. PubMed PMID: 23090987; PubMed Central PMCID: PMCPMC3499012.
   PubMed Web of Science ®Google Scholar
• Lassman AB, Pugh SL, Gilbert MR, et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 2015 Jul;17(7):992–998. PubMed PMID: 25758746; PubMed Central PMCID: PMCPMC5762006.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1100–1108. PubMed PMID: 25163906.
   PubMed Web of Science ®Google Scholar
• Nazarenko I, Hede SM, He X, et al. PDGF and PDGF receptors in glioma. Ups J Med Sci. 2012 May;117(2):99–112. PubMed PMID: 22509804; PubMed Central PMCID: PMCPMC3339542.
   PubMed Web of Science ®Google Scholar
• Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol. 2010 Feb;96(3):393–402. PubMed PMID: 19688297.
   PubMed Web of Science ®Google Scholar
• Razis E, Selviaridis P, Labropoulos S, et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 2009 Oct 1;15(19):6258–6266. PubMed PMID: 19789313.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Dresemann G, Taillibert S, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009 Dec 15;101(12):1995–2004. PubMed PMID: 19904263; PubMed Central PMCID: PMCPMC2795431.
   PubMed Web of Science ®Google Scholar
• Nakada M, Kita D, Watanabe T, et al. Aberrant signaling pathways in glioma. Cancers (Basel). 2011 Aug 10;3(3):3242–3278. PubMed PMID: 24212955; PubMed Central PMCID: PMCPMC3759196.
   PubMedGoogle Scholar
• Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug;23(4):357–361. PubMed PMID: 16012795.
   PubMed Web of Science ®Google Scholar
• Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res. 2013 Apr;33(4):1657–1660. PubMed PMID: 23564811.
   PubMed Web of Science ®Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010 Mar 1;28(7):1168–1174. PubMed PMID: 20124186; PubMed Central PMCID: PMCPMC2834468.
   PubMed Web of Science ®Google Scholar
• Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007 Oct 12;318(5848):287–290. PubMed PMID: 17872411.
   PubMed Web of Science ®Google Scholar
• Wang H, Xu T, Jiang Y, et al. The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia. 2015 Mar;17(3):239–255. PubMed PMID: 25810009; PubMed Central PMCID: PMCPMC4372648.
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Liu L, Ichimura K, et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993 Jun 15;53(12):2736–2739. PubMed PMID: 8504413.
   PubMed Web of Science ®Google Scholar
• Daniele S, Costa B, Zappelli E, et al. Combined inhibition of AKT/mTOR and MDM2 enhances glioblastoma multiforme cell apoptosis and differentiation of cancer stem cells. Sci Rep. 2015 Apr 21;5:9956. PubMed PMID: 25898313; PubMed Central PMCID: PMCPMC4404683.
   PubMed Web of Science ®Google Scholar
• Verreault M, Schmitt C, Goldwirt L, et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glioblastomas. Clin Cancer Res. 2016 Mar 1;22(5):1185–1196. PubMed PMID: 26482041; PubMed Central PMCID: PMCPMC4842012.
   PubMed Web of Science ®Google Scholar
• Touat M, Idbaih A, Sanson M, et al. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017 Jul 1;28(7):1457–1472. PubMed PMID: 28863449; PubMed Central PMCID: PMCPMC5834086.
   PubMed Web of Science ®Google Scholar
• Xu J, Sampath D, Lang FF, et al. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol. 2011 Nov;105(2):241–251. PubMed PMID: 21598070; PubMed Central PMCID: PMCPMC3794467.
   PubMed Web of Science ®Google Scholar
• Cornago M, Garcia-Alberich C, Blasco-Angulo N, et al. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis. 2014 Oct 2;5:e1435. PubMed PMID: 25275596; PubMed Central PMCID: PMCPMC4237242.
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009 Apr 20;27(12):2052–2058. PubMed PMID: 19307505; PubMed Central PMCID: PMCPMC2669764.
   PubMed Web of Science ®Google Scholar
• Vk P, Wu J, Yuan Y, et al. Brain tumor trials collaborative bayesian adaptive randomized phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). J Clin Oncol. 2015;33(15_suppl):2012.
   Web of Science ®Google Scholar
• Rubsam LZ, Boucher PD, Murphy PJ, et al. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 1999 Feb 1;59(3):669–675. PubMed PMID: 9973216.
   PubMed Web of Science ®Google Scholar
• Zhao F, Tian J, An L, et al. Prognostic utility of gene therapy with herpes simplex virus thymidine kina for patients with high-grade malignant gliomas: a systematic review and meta analysis. J Neurooncol. 2014 Jun;118(2):239–246. PubMed PMID: 24756350; eng.
   PubMed Web of Science ®Google Scholar
• Ostertag D, Amundson KK, Lopez Espinoza F, et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012 Feb;14(2):145–159. PubMed PMID: 22070930; PubMed Central PMCID: PMCPMC3266384.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Vogelbaum MA, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018 Sep 3;20(10):1383–1392. PubMed PMID: 29762717; PubMed Central PMCID: PMCPMC6120351. eng.
   PubMed Web of Science ®Google Scholar
• Jiang H, Clise-Dwyer K, Ruisaard KE, et al. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014;9(5):e97407. PubMed PMID: 24827739; PubMed Central PMCID: PMCPMC4020829. eng.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I Study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018 May 10;36(14):1419–1427. PubMed PMID: 29432077; PubMed Central PMCID: PMCPMC6075856. eng.
   PubMed Web of Science ®Google Scholar
• Ea C, Yu J, Phuphanich S, et al. Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: tolerability and survival in recurrent glioblastoma. J Clin Oncol. 2017;35(15_suppl):2044.
   PubMed Web of Science ®Google Scholar
• Mohyeldin A, Chiocca EA. Gene and viral therapy for glioblastoma: a review of clinical trials and future directions. Cancer J. 2012 Jan–Feb;18(1):82–88. PubMed PMID: 22290261; eng.
   PubMed Web of Science ®Google Scholar
• Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011 Mar 15;17(6):1603–1615. PubMed PMID: 21135147; PubMed Central PMCID: PMCPMC3071163.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018 Jul 12;379(2):150–161. PubMed PMID: 29943666; PubMed Central PMCID: PMCPMC6065102. eng.
   PubMed Web of Science ®Google Scholar
• Muragaki Y, Maruyama T, Iseki H, et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. J Neurosurg. 2011 Aug;115(2):248–255. PubMed PMID: 21568657.
   PubMed Web of Science ®Google Scholar
• Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965–2969. PubMed PMID: 1557402; PubMed Central PMCID: PMCPMC48784.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar;13(3):324–333. PubMed PMID: 21149254; PubMed Central PMCID: PMCPMC3064599.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Mitchell DA, et al. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol. 2008 Oct;20(5):267–275. PubMed PMID: 18539480; PubMed Central PMCID: PMCPMC2633865.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009 Oct;8(10):2773–2779. PubMed PMID: 19825799; PubMed Central PMCID: PMCPMC2991139.
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1373–1385. PubMed PMID: 28844499.
   PubMed Web of Science ®Google Scholar
• Powers MV, Jones K, Barillari C, et al. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle. 2010 Apr 15;9(8):1542–1550. PubMed PMID: 20372081.
   PubMed Web of Science ®Google Scholar
• Young JC, Agashe VR, Siegers K, et al. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol. 2004 Oct;5(10):781–791. PubMed PMID: 15459659.
   PubMed Web of Science ®Google Scholar
• Crane CA, Han SJ, Ahn B, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013 Jan 1;19(1):205–214. PubMed PMID: 22872572.
   PubMed Web of Science ®Google Scholar
• Bloch O, Crane CA, Fuks Y, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan;16(2):274–279. PubMed PMID: 24335700; PubMed Central PMCID: PMCPMC3895386. eng.
   PubMed Web of Science ®Google Scholar
• Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001 Dec;1(3):220–228. PubMed PMID: 11905831.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009 Aug 3;206(8):1717–1725. PubMed PMID: 19581407; PubMed Central PMCID: PMCPMC2722174.
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008 Oct 10;322(5899):271–275. PubMed PMID: 18845758.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009 Dec 21;206(13):3015–3029. PubMed PMID: 20008522; PubMed Central PMCID: PMCPMC2806460.
   PubMed Web of Science ®Google Scholar
• Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009 Mar 12;458(7235):206–210. PubMed PMID: 19078956; PubMed Central PMCID: PMCPMC2753387.
   PubMed Web of Science ®Google Scholar
• Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007 Jan;13(1):84–88. PubMed PMID: 17159987.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–2454. PubMed PMID: 22658127; PubMed Central PMCID: PMCPMC3544539. eng.
   PubMed Web of Science ®Google Scholar
• Maxwell R, Jackson CM, Lim M. Clinical trials investigating immune checkpoint blockade in glioblastoma. Curr Treat Options Oncol. 2017 Aug;18(8):51. PubMed PMID: 28785997; eng.
   PubMed Web of Science ®Google Scholar
• Simonelli M, Persico P, Perrino M, et al. Checkpoint inhibitors as treatment for malignant gliomas: “A long way to the top”. Cancer Treat Rev. 2018 Sep;69:121–131. PubMed PMID: 29966936; eng.
   PubMed Web of Science ®Google Scholar
• Tan AC, Heimberger AB, Khasraw M. Immune Checkpoint Inhibitors in Gliomas. Curr Oncol Rep. 2017 Apr;19(4):23. PubMed PMID: 28303490; eng.
   PubMed Web of Science ®Google Scholar
• Kamran N, Calinescu A, Candolfi M, et al. Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther. 2016 Oct;16(10):1245–1264. PubMed PMID: 27411023; PubMed Central PMCID: PMCPMC5014608. eng.
   PubMed Web of Science ®Google Scholar
• Platten M, Bunse L, Wick W, et al. Concepts in glioma immunotherapy. Cancer Immunol Immunother. 2016 Oct;65(10):1269–1275. PubMed PMID: 27460064; eng.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720–724. PubMed PMID: 8421711; PubMed Central PMCID: PMCPMC45737.
   PubMed Web of Science ®Google Scholar
• Miao H, Choi BD, Suryadevara CM, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One. 2014;9(4):e94281. PubMed PMID: 24722266; PubMed Central PMCID: PMCPMC3983153.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell therapy. N Engl J Med. 2016 Dec 29;375(26):2561–2569. PubMed PMID: 28029927; PubMed Central PMCID: PMCPMC5390684. eng.
   PubMed Web of Science ®Google Scholar
• Everson RG, Antonios JP, Liau LM. Cell-based immunotherapy of gliomas. Prog Neurol Surg. 2018;32:90–100. PubMed PMID: 29990977; eng.
   PubMedGoogle Scholar
• Lin Y, Okada H. Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther. 2016 Oct;16(10):1265–1275. PubMed PMID: 27434205; PubMed Central PMCID: PMCPMC5133460. eng.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011 Dec 13;20(6):810–817. PubMed PMID: 22137795; eng.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015 May;47(5):458–468. PubMed PMID: 25848751; eng.
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009–4014. PubMed PMID: 23412337; PubMed Central PMCID: PMCPMC3593922. eng.
   PubMed Web of Science ®Google Scholar
• Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20;344(6190):1396–1401. PubMed PMID: 24925914; PubMed Central PMCID: PMCPMC4123637. eng.
   PubMed Web of Science ®Google Scholar
• Lee J-K, Wang J, Sa JK, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. 2017 Apr;49(4):594–599. PubMed PMID: 28263318; PubMed Central PMCID: PMCPMC5627771. eng.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–486.
   PubMed Web of Science ®Google Scholar